Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Monotherapy in Chinese Patients with R/R DLBCL
NCT04657302Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 3.5 years, Serum Concentration of Glofitamab up to 3.5 years and 8 more. Started Jan 2021; status: completed.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04657302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657302.